Asymptomatic SARS-CoV-2 Vaccine Breakthrough Infections in Health Care Workers Identified Through Routine Universal Surveillance Testing

Background: Concerns exist about the efficacy of COVID-19 vaccines against immune escape by viral variants of concern (VOCs): Delta is currently the most common VOC worldwide (1), and nasopharyngeal swabs (NPSs) show that fully vaccinated persons, like unvaccinated persons, harbor infectious viral loads (2). Reports to date have assessed the prevalence of vaccine breakthrough (VBT) infection among health care workers (HCWs), mostly based on spontaneous self-reporting by
symptomatic HCWs and hence missing asymptomatic persons, who could nevertheless transmit the pathogen. Once a positive result is identified in an HCW, most countries ask for a 14-day quarantine or 2 consecutive follow-ups after at least 10 days before the HCW is admitted back to the workplace. Such mandatory quarantines can lead to large HCW shortages and cause health crises in hospitals.

Objective: To systematically surveil 2397 HCWs fully vaccinated with BNT162 at the ASST Settaliani hospitals (Lombardy, Italy) in February 2021.

Methods and Findings: Since March 2021, hospital directive IGG02PG32/2021 has classified wards according to risk for infection from attending patients and mandated surveillance of HCWs. Fully vaccinated HCWs (n = 2397) who worked in 8 wards deemed to be at “high risk” had a mandatory NPS with SARS-CoV-2 polymerase chain reaction (PCR) testing every 2 weeks, and those in 8 “moderate-risk” wards were tested every 4 weeks. The screening used 1 of 2 real-time PCR tests (m2000 RealTime System or Alinity m SARS-CoV-2 Assay [Abbott]). If SARS-CoV-2 RNA was detected, the HCW was tested with daily NPSs until 2 consecutive NPSs were negative for SARS-CoV-2. Positive samples with cycle thresholds below 25 were retested by spike gene sequencing; positive samples with cycle thresholds between 25 and 35 were retested with a VOC-specific multiplex real-time PCR (SARS-CoV-2 Extended ELITe MGB Kit [ELITechGroup]) targeting L452R, E484K, and N501Y. A voluntary postvaccine serologic program was implemented using the ULIAISON SARS-CoV-2 S1/S2 IgG assay (DiaSorin).

Between 15 March and 17 August 2021, we identified 33 cases of SARS-CoV-2 infection as part of the surveillance program, 17 among 789 HCWs (2.1%) in the high-risk group tested every 2 weeks and 16 among 1387 HCWs (1.1%) in the moderate-risk group tested every 4 weeks; none of these case patients ever developed symptoms, and none had immune deficiency or significant comorbid conditions. Five cases were further characterized by spike gene sequencing and 12 by VOC-specific real-time PCR. The Figure presents cases and background community prevalence of COVID-19 during the study period. During the same interval, 8 HCWs (0.4%) tested positive while symptomatic; only 1 variant could be characterized as Alpha by sequencing. The Table presents characteristics of HCWs according to surveillance results and symptoms. All 33 asymptomatic case patients tested negative the day after the initial positive result, and all negative results were confirmed on a third NPS 2 days afterward. In contrast, symptomatic cases cleared after a mean of 11 days. The mean IgG level was twice as high in the asymptomatic than the symptomatic group.

Discussion: Our results indicate that systematic surveillance of asymptomatic vaccinated HCWs uncovers many times more cases of VBT infection than symptom-based testing. The incidence of asymptomatic VBT infections seemed to depend on the frequency of VBT infection than symptom-based testing. The incidence of asymptomatic vaccinated HCWs uncovers many times more cases of VBT infection than symptom-based testing. The incidence of asymptomatic VBT infections seemed to depend on the frequency of VBT infection than symptom-based testing. The incidence of asymptomatic vaccinated HCWs uncovers many times more cases of VBT infection than symptom-based testing. The incidence of asymptomatic VBT infections seemed to depend on the frequency of VBT infection than symptom-based testing. The incidence of asymptomatic vaccinated HCWs uncovers many times more cases of VBT infection than symptom-based testing. The incidence of asymptomatic VBT infections seemed to depend on the frequency of VBT infection than symptom-based testing. The incidence of asymptomatic vaccinated HCWs uncovers many times more cases of VBT infection than symptom-based testing. The incidence of asymptomatic VBT infections seemed to depend on the frequency of VBT infection than symptom-based testing.
details on time to viral clearance (5)—consistent with our estimates of symptomatic cases. All of these studies were done at times when Alpha was the dominant SARS-COV-2 variant, whereas our study was mostly run during the Delta predominance.

Study limitations include the inability to perform genetic sequencing for more accurate VOC imputation in patients with cycle thresholds above 25 and the lack of viral neutralization assays to assess neutralizing antibody levels. We likely missed a large proportion of asymptomatic VBT infections cleared during intervals between NPSs.

Our findings suggest that regular testing of asymptomatic vaccinated HCWs who tested positive for SARS-CoV-2 may preclude the need for long quarantines, but this requires confirmation in larger studies. Surveillance programs aimed at capturing all VBT infections would need to include frequent testing. In the absence of such frequent surveillance, maintaining vigilant use of personal protective equipment seems to be warranted.

Federica Novazzi, PhD
Laboratory of Microbiology, ASST Sette Laghi, Varese, Italy

Stefano Taborelli, MD
Unit of Occupational Medicine, ASST Sette Laghi, Varese, Italy

Andreina Baj, MD, PhD
Laboratory of Microbiology, ASST Sette Laghi, and Department of Medicine and Surgery, University of Insubria, Varese, Italy

Daniele Focosi, MD, PhD
North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy

Fabrizio Maggi, MD, PhD
Laboratory of Microbiology, ASST Sette Laghi, and Department of Medicine and Surgery, University of Insubria, Varese, Italy

Disclosures: Authors have reported no disclosures of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms. do?mNum=M21-3486.

Reproducible Research Statement: Study protocol and data set: Available from Prof. Maggi (e-mail, fabrizio.maggi@uninsubria.it). Statistical code: Not available.

Corresponding Author: Andreina Baj, MD, PhD, Microbiology Unit, Ospedale di Circolo e Fondazione Macchi, Viale Luigi Borri, 57, 21100 Varese, Italy; e-mail, andreina.baj@uninsubria.it.

This article was published at Annals.org on 19 October 2021.

doi:10.7326/M21-3486

References
1. Farinholt T, Doddapaneni H, Qin X, et al. Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections. medRxiv. 2021. [PMID: 34268529] doi:10.1101/2021.06.28.21258780
2. Riemersma KK, Grogan BE, Kita-Yarbro A, et al. Vaccinated and unvaccinated individuals have similar viral loads in communities with a high prevalence of the SARS-CoV-2 Delta variant. medRxiv. Preprint posted online 31 July 2021. doi:10.1101/2021.07.31.21261387
3. Benenson S, Oster Y, Cohen MJ, et al. BNT162b2 mRNA Covid-19 vaccine effectiveness among health care workers [Letter]. N Engl J Med. 2021;384:1775-1777. [PMID: 33755373] doi:10.1056/NEJMc2101951
4. Keenher J, Horton LE, Pfeffer MA, et al. SARS-CoV-2 infection after vaccination in health care workers in California [Letter]. N Engl J Med. 2021;384:1774-1775. [PMID: 33755376] doi:10.1056/NEJMct2101927
5. Rovida F, Cassaniti I, Paolucci S, et al. SARS-CoV-2 vaccine breakthrough infections are asymptomatic or mildly symptomatic and are infrequently transmitted. medRxiv. Preprint posted online 3 July 2021. doi:10.1101/2021.06.29.21259500

Table. Mean Characteristics in the 3 HCW Cohorts (Asymptomatically Infected HCWs, Noninfected HCWs, and Symptomatically Infected HCWs)

| Variable | Noninfected HCWs During the Study (n = 2176)* | Asymptomatically Infected, Vaccinated HCWs Diagnosed Through Surveillance During the Study (n = 33) | Infected, Vaccinated HCWs Diagnosed Because of Symptoms During the Study (n = 8) |
|----------|-----------------------------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Mean age (SD), y | 46 (10) | 43 (11) | 52 (8) |
| Sex, n | | | |
| Female | 1631 | 25 | 7 |
| Male | 545 | 8 | 1 |
| Mean real-time PCR Ct (SD) | NA | 31 (6) | 30 (4) |
| Mean time since second BNT162b2 dose (SD), d | NA | 119 (38) | 75 (39) |
| Mean time to viral clearance (SD), d | NA | 1 (0) | 11 (2) |
| Mean serum IgG level after second BNT162b2 dose (SD), AU/mL | 320 (27)† | 343 (130)‡ | 142 (26)‡ |

Ct = cycle threshold; HCW = health care worker; NA = not applicable; PCR = polymerase chain reaction.

* 221 of 2397 HCWs did not adhere to the testing schedule, and analyses were run for the remaining 2176 HCWs.
† Calculated on a subgroup of 804 HCWs.
‡ Calculated on a subgroup of 23 HCWs.